Developer docs
API playgroundTry for free, no card

Search company profiles

Evommune

Full company profile

uuid00007tk

Namestring
Evommune
Legal namestring
Evommune, Inc.
Websiteurl
evommune.com
Company typeenum
Public
Founded yearint
2020
Descriptiontext

Evommune, Inc. is a clinical-stage biotechnology company founded in 2020 and headquartered in Palo Alto, California, focused on developing differentiated therapies for chronic inflammatory diseases. The company's pipeline is built around two core platforms: EVO756, a selective small molecule antagonist of the Mas-related G-protein coupled receptor X2 (MRGPRX2) being developed as a potential first oral treatment for chronic spontaneous urticaria, atopic dermatitis, and migraine; and EVO301, an anti-serum albumin Fab-associated (SAFA) IL-18 binding protein fusion designed to neutralize IL-18 activity in atopic dermatitis and ulcerative colitis. EVO756 has completed Phase 2a in atopic dermatitis (33% placebo-adjusted EASI improvement at Week 12, 23% IGA 0/1 response) and completed Phase 2b enrollment for chronic spontaneous urticaria with topline data expected Q2 2026, while EVO301 has met its Phase 2a primary endpoint.

The company operates a licensing-based revenue model anchored by a strategic collaboration with Maruho Co., Ltd. covering exclusive development and commercialization of EVO756 in Japan, Greater China, and other key Asian markets, which drove $13.0 million in full-year 2025 revenue (up from $7.0 million in 2024). Evommune has no approved products and is pre-commercial, planning to leverage enterprise field sales upon regulatory approval. The company is publicly traded on NYSE under ticker EVMN following a November 2025 IPO that raised $172.5 million, supplemented by a February 2026 private placement of approximately $125 million, with $307 million in cash and investments reported as of March 31, 2026 — disclosed as sufficient to fund operations through 2028. Leadership includes co-founders Luis Peña (President & CEO, previously co-founder of Dermira acquired by Eli Lilly for $1.1 billion) and Eugene A. Bauer, M.D. (CMO, ex-founder of Dermira and Peplin), along with a management team largely drawn from Kadmon (acquired by Sanofi for $1.9 billion).

Short descriptiontext

Evommune is a clinical-stage biotechnology company developing oral and biologic therapies for chronic inflammatory diseases via MRGPRX2 antagonism (EVO756) and IL-18BP fusion protein engineering (EVO301), targeting chronic spontaneous urticaria, atopic dermatitis, migraine, and ulcerative colitis. Public on NYSE since November 2025.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, chronic inflammatory diseases, MRGPRX2 antagonist therapy, IL-18BP fusion protein, small molecule therapeutics
Industry3 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals — Inflammatory Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing Revenue
TypeLicensing Royalties
Description

Evommune generates revenue through strategic licensing collaborations. The company entered into a strategic collaboration with Maruho Co., Ltd. to exclusively develop and commercialize EVO756 in Japan, Greater China, and other key Asian markets. Revenue for full year 2025 increased to $13.0 million compared to $7.0 million in 2024, driven by this licensing collaboration.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Evommune is a clinical-stage biotechnology company developing differentiated product candidates that target key drivers of chronic inflammatory diseases. Its lead programs are EVO756, an oral small molecule antagonist of the MRGPRX2 receptor being developed for chronic spontaneous urticaria, atopic dermatitis, and migraine, and EVO301, a SAFA IL-18BP fusion protein for atopic dermatitis and ulcerative colitis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • EVO756 achieved 33% placebo-adjusted improvement in EASI score at Week 12 in Phase 2a atopic dermatitis trial
+3 more records
Product overview1 text field

Evommune is a clinical-stage biotechnology company advancing a pipeline of differentiated product candidates for chronic inflammatory diseases. The company's portfolio consists of two main investigational therapies: EVO756, an oral small molecule MRGPRX2 antagonist currently in Phase 2 trials for chronic spontaneous urticaria, atopic dermatitis, and migraine; and EVO301, an IL-18BP fusion protein in Phase 2a development for atopic dermatitis and ulcerative colitis.

Product and service2 records
1EVO756
CategoryClinical-stage therapeutic candidate (small molecule)
Description

Investigational oral small molecule antagonist of the MRGPRX2 receptor, being developed for chronic spontaneous urticaria, atopic dermatitis, and migraine by targeting mast cell-mediated inflammation.

2EVO301
CategoryClinical-stage therapeutic candidate (biologic fusion protein)
Description

Investigational anti-serum albumin Fab-associated (SAFA) IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity, in development for atopic dermatitis and ulcerative colitis.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Maruho Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Evommune entered into a strategic collaboration with Maruho Co., Ltd., a globally respected pharmaceutical organization that has developed and commercialized pharmaceuticals in Japan for more than 100 years. The partnership exclusively licenses development and commercialization of EVO756 (MRGPRX2 small molecule antagonist) in Japan, Greater China, and other key Asian markets. The collaboration marks a long-term, multifaceted relationship with potential to accelerate development and expand patient access to EVO756 across Asia.

evommune.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-11-01
Description

Evommune and Accutar formed a partnership focused on the discovery of novel small molecule drug candidates targeting the root cause of chronic inflammatory diseases. Accutar employs a sophisticated hybrid approach integrating computational drug design with wet lab validation, overcoming limitations of traditional drug discovery methods. By combining Evommune's deep biological expertise with Accutar's medicinal chemistry engine, the companies aim to develop next-generation therapies for chronic inflammatory diseases.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pharma with Rinvoq (upadacitinib) and Skyrizi competing in atopic dermatitis and ulcerative colitis. Defines the competitive efficacy and safety bar Evommune's oral therapies must exceed.

TypeDirect peer
Description

Late-stage dermatology-focused biotech commercializing topical therapies for inflammatory skin diseases (atopic dermatitis, seborrheic dermatitis). Closely aligned business model of developing differentiated therapies for chronic inflammatory skin conditions.

TypeDirect peer
Description

Clinical-stage immunology biotech developing antibodies for inflammatory diseases, including atopic dermatitis and other IL-pathway-driven conditions. Directly comparable in mechanism (cytokine modulation) and target indications.

TypeDirect peer
Description

Clinical-stage biotech developing Nanobody therapy (sonelokimab) for inflammatory skin and joint diseases including atopic dermatitis and hidradenitis suppurativa. Direct competitor in inflammation dermatology with similar stage of development.

TypeDirect peer
Description

Clinical-stage dermatology and immunology biotech developing therapies for inflammatory skin diseases and immuno-inflammatory conditions. Comparable size, pipeline scope, and target disease areas.

TypeEmerging player
Description

Clinical-stage inflammation/immunology biotech focused on T-cell-driven inflammatory diseases including atopic dermatitis. Comparable in stage, indication overlap, and therapeutic approach.

TypeBroad incumbent
Description

Established commercial biotech with multiple approved immunology/inflammation products including ruxolitinib cream (Opzelura) for atopic dermatitis. Competes in the same indications with broader portfolio and commercial infrastructure.

TypeBroad incumbent
Description

Major pharma with lebrikizumab and OLUMIANT in atopic dermatitis. Acquired Evommune co-founders' prior company (Dermira) and represents a potential strategic acquirer or major competitor depending on data.

TypeBroad incumbent
Description

Global dermatology-focused pharma with a portfolio of prescription and aesthetic treatments. Represents the established dermatology commercial infrastructure that Evommune may eventually need to partner with or build toward.

TypeBroad incumbent
Description

Commercializes Dupixent (with Regeneron), the dominant biologic in atopic dermatitis and CSU. Sets the standard of care against which Evommune's oral MRGPRX2 antagonist will be benchmarked.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors25 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evommune

Biopharmaceuticals — Inflammatory Disease Therapeuticsevommune.com

Evommune is a clinical-stage biotechnology company developing oral and biologic therapies for chronic inflammatory diseases via MRGPRX2 antagonism (EVO756) and IL-18BP fusion protein engineering (EVO301), targeting chronic spontaneous urticaria, atopic dermatitis, migraine, and ulcerative colitis. Public on NYSE since November 2025.

What Evommune does

Evommune, Inc. is a clinical-stage biotechnology company founded in 2020 and headquartered in Palo Alto, California, focused on developing differentiated therapies for chronic inflammatory diseases. The company's pipeline is built around two core platforms: EVO756, a selective small molecule antagonist of the Mas-related G-protein coupled receptor X2 (MRGPRX2) being developed as a potential first oral treatment for chronic spontaneous urticaria, atopic dermatitis, and migraine; and EVO301, an anti-serum albumin Fab-associated (SAFA) IL-18 binding protein fusion designed to neutralize IL-18 activity in atopic dermatitis and ulcerative colitis. EVO756 has completed Phase 2a in atopic dermatitis (33% placebo-adjusted EASI improvement at Week 12, 23% IGA 0/1 response) and completed Phase 2b enrollment for chronic spontaneous urticaria with topline data expected Q2 2026, while EVO301 has met its Phase 2a primary endpoint.

The company operates a licensing-based revenue model anchored by a strategic collaboration with Maruho Co., Ltd. covering exclusive development and commercialization of EVO756 in Japan, Greater China, and other key Asian markets, which drove $13.0 million in full-year 2025 revenue (up from $7.0 million in 2024). Evommune has no approved products and is pre-commercial, planning to leverage enterprise field sales upon regulatory approval. The company is publicly traded on NYSE under ticker EVMN following a November 2025 IPO that raised $172.5 million, supplemented by a February 2026 private placement of approximately $125 million, with $307 million in cash and investments reported as of March 31, 2026 — disclosed as sufficient to fund operations through 2028. Leadership includes co-founders Luis Peña (President & CEO, previously co-founder of Dermira acquired by Eli Lilly for $1.1 billion) and Eugene A. Bauer, M.D. (CMO, ex-founder of Dermira and Peplin), along with a management team largely drawn from Kadmon (acquired by Sanofi for $1.9 billion).

Evommune firmographics

Firmographics
Name
Evommune
Legal name
Evommune, Inc.
Website
https://evommune.com
Company type
Public
Founded year
2020
Operating status
Ipo
Headcount range
51–100 employees
Short description
Evommune is a clinical-stage biotechnology company developing oral and biologic therapies for chronic inflammatory diseases via MRGPRX2 antagonism (EVO756) and IL-18BP fusion protein engineering (EVO301), targeting chronic spontaneous urticaria, atopic dermatitis, migraine, and ulcerative colitis. Public on NYSE since November 2025.
Ownership category
akta.pro rank

Evommune industry classification

Industry
Product category
Biopharmaceuticals — Inflammatory Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Clinical-stage biotechnology
  • Chronic inflammatory diseases
  • MRGPRX2 antagonist therapy
  • IL-18BP fusion protein
  • Small molecule therapeutics

Where Evommune is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Evommune business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing Revenue: Evommune generates revenue through strategic licensing collaborations. The company entered into a strategic collaboration with Maruho Co., Ltd. to exclusively develop and commercialize EVO756 in Japan, Greater China, and other key Asian markets. Revenue for full year 2025 increased to $13.0 million compared to $7.0 million in 2024, driven by this licensing collaboration.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Evommune product offering

Product offering

Core offering

Evommune is a clinical-stage biotechnology company developing differentiated product candidates that target key drivers of chronic inflammatory diseases. Its lead programs are EVO756, an oral small molecule antagonist of the MRGPRX2 receptor being developed for chronic spontaneous urticaria, atopic dermatitis, and migraine, and EVO301, a SAFA IL-18BP fusion protein for atopic dermatitis and ulcerative colitis.

Product overview

Evommune is a clinical-stage biotechnology company advancing a pipeline of differentiated product candidates for chronic inflammatory diseases. The company's portfolio consists of two main investigational therapies: EVO756, an oral small molecule MRGPRX2 antagonist currently in Phase 2 trials for chronic spontaneous urticaria, atopic dermatitis, and migraine; and EVO301, an IL-18BP fusion protein in Phase 2a development for atopic dermatitis and ulcerative colitis.

Differentiator

Problem solved

Functional benefit

Products and services

  • EVO756 Investigational oral small molecule antagonist of the MRGPRX2 receptor, being developed for chronic spontaneous urticaria, atopic dermatitis, and migraine by targeting mast cell-mediated inflammation.
  • EVO301 Investigational anti-serum albumin Fab-associated (SAFA) IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity, in development for atopic dermatitis and ulcerative colitis.

Quantifiable outcome

  • EVO756 achieved 33% placebo-adjusted improvement in EASI score at Week 12 in Phase 2a atopic dermatitis trial
  • +3 more outcomes

Companies that use Evommune

Customer profile

Segments4 records

Ideal customer profiles2 records

Evommune technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Evommune partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Maruho Co., Ltd.coreStrategic or Co-development Partner · 1 March 2024Evommune entered into a strategic collaboration with Maruho Co., Ltd., a globally respected pharmaceutical organization that has developed and commercialized pharmaceuticals in Japan for more than 100 years. The partnership exclusively licenses development and commercialization of EVO756 (MRGPRX2 small molecule antagonist) in Japan, Greater China, and other key Asian markets. The collaboration marks a long-term, multifaceted relationship with potential to accelerate development and expand patient access to EVO756 across Asia.
  • Accutar BiotechnologycoreTechnology or Integration · 1 November 2023Evommune and Accutar formed a partnership focused on the discovery of novel small molecule drug candidates targeting the root cause of chronic inflammatory diseases. Accutar employs a sophisticated hybrid approach integrating computational drug design with wet lab validation, overcoming limitations of traditional drug discovery methods. By combining Evommune's deep biological expertise with Accutar's medicinal chemistry engine, the companies aim to develop next-generation therapies for chronic inflammatory diseases.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Evommune competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Major pharma with Rinvoq (upadacitinib) and Skyrizi competing in atopic dermatitis and ulcerative colitis. Defines the competitive efficacy and safety bar Evommune's oral therapies must exceed.
  • Incyte Corporation: Established commercial biotech with multiple approved immunology/inflammation products including ruxolitinib cream (Opzelura) for atopic dermatitis. Competes in the same indications with broader portfolio and commercial infrastructure.
  • Eli Lilly: Major pharma with lebrikizumab and OLUMIANT in atopic dermatitis. Acquired Evommune co-founders' prior company (Dermira) and represents a potential strategic acquirer or major competitor depending on data.
  • Galderma: Global dermatology-focused pharma with a portfolio of prescription and aesthetic treatments. Represents the established dermatology commercial infrastructure that Evommune may eventually need to partner with or build toward.
  • Sanofi: Commercializes Dupixent (with Regeneron), the dominant biologic in atopic dermatitis and CSU. Sets the standard of care against which Evommune's oral MRGPRX2 antagonist will be benchmarked.

Direct peers

  • Arcutis Biotherapeutics: Late-stage dermatology-focused biotech commercializing topical therapies for inflammatory skin diseases (atopic dermatitis, seborrheic dermatitis). Closely aligned business model of developing differentiated therapies for chronic inflammatory skin conditions.
  • AnaptysBio: Clinical-stage immunology biotech developing antibodies for inflammatory diseases, including atopic dermatitis and other IL-pathway-driven conditions. Directly comparable in mechanism (cytokine modulation) and target indications.
  • MoonLake Immunotherapeutics: Clinical-stage biotech developing Nanobody therapy (sonelokimab) for inflammatory skin and joint diseases including atopic dermatitis and hidradenitis suppurativa. Direct competitor in inflammation dermatology with similar stage of development.
  • Aclaris Therapeutics: Clinical-stage dermatology and immunology biotech developing therapies for inflammatory skin diseases and immuno-inflammatory conditions. Comparable size, pipeline scope, and target disease areas.

Emerging players

  • Connect Biopharma: Clinical-stage inflammation/immunology biotech focused on T-cell-driven inflammatory diseases including atopic dermatitis. Comparable in stage, indication overlap, and therapeutic approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Evommune social profiles

Digital presence

Evommune financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evommune leadership team

Management profile

Number of profiles

Profiles17 records

Evommune funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evommune M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evommune

What does Evommune do?

Evommune is a clinical-stage biotechnology company developing differentiated product candidates that target key drivers of chronic inflammatory diseases. Its lead programs are EVO756, an oral small molecule antagonist of the MRGPRX2 receptor being developed for chronic spontaneous urticaria, atopic dermatitis, and migraine, and EVO301, a SAFA IL-18BP fusion protein for atopic dermatitis and ulcerative colitis.

Is Evommune a public or private company?

Evommune is a public company. It is classified as public and is currently ipo.

When was Evommune founded?

Evommune was founded in 2020. It employs 51 to 100 people.

Where is Evommune based?

Evommune is headquartered in Palo Alto, United States, in the North America region.

How does Evommune make money?

One revenue line is on record: licensing Revenue.

Who are Evommune's main competitors?

Broad incumbents on record are AbbVie, Incyte Corporation, Eli Lilly, Galderma and Sanofi. Direct peers are Arcutis Biotherapeutics, AnaptysBio, MoonLake Immunotherapeutics and Aclaris Therapeutics. Connect Biopharma is listed as an emerging player.

Does Evommune have an API?

No public API is recorded for Evommune.

What industry is Evommune in?

Evommune's product category is Biopharmaceuticals — Inflammatory Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comEvommune at jefferies global healthcare conference: pipeline grows, cash holdsEvommune presented its pipeline at the Jefferies Global Healthcare Conference, highlighting $290 million in cash and a lead drug EVO301 that showed mid-30% separation versus placebo in phase IIa atopic dermatitis data. Three additional programs—migraine, VAV1 degrader, and TLR7/8 antagonist—enter the clinic in 2027, with data readouts expected through 2028.TradingViewEvommune approves retention awards and option repricing for three executivesEvommune approved cash retention awards and repriced stock options for CEO Luis Peña, CFO Kyle Carver, and Chief Business & Legal Officer Gregory Moss. The awards total $1,846,600, and options were repriced to $7.63 per share, effective November 13, 2026.TradingViewNeedham maintains Evommune at Buy, lowers price target to $25 from $28Needham maintained Evommune at Buy and lowered its price target to $25 from $28, a 10.7% decrease. The price target implies an upside of 211.7% from the Nov 12 close of $8.02.Longevity.TechnologyEvommune bets $30m upfront on a new autoimmune drugEvommune licensed oral VAV1 degrader EVO570 from Hinova Pharmaceuticals for $30 million upfront. The deal includes milestones totaling about $1.1 billion, with a Phase 1 trial starting soon. The company has already paid for the trial.TradingViewEvommune, Inc. Stock 12‑Month Price Target Cut to $22.5, Implies 181% UpsideAnalysts' average price target for Evommune, Inc. fell from $22.8 to $22.5, implying about 181% upside from the Nov. 12 closing price. The consensus remains a Buy across 13 analysts, with 10 Buys, 3 Holds, and 0 Sells.Seeking AlphaEvommune, Inc. GAAP EPS of -$0.85 beats by $0.01Evommune, Inc. reported Q3 GAAP EPS of -$0.85, beating by $0.01. The stock fell 6.96% to $8.02, with a market cap of $312.84M and revenue growth of 233.33% year-over-year.MarketBeatEvommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund DevelopmentEvommune licensed global development rights to EVO570, an experimental oral arthritis drug, to Hinova for $20M cash and $10M in warrants. The company raised $30M in a private placement to fund phase I and II trials, with phase I expected to start in January 2027. The company expects rheumatoid arthritis data in Q4 2028.The Pharma LetterEvommune in-licenses EVO570 from Hinova Pharma for $1.1BEvommune in-licensed EVO570 from Hinova Pharma for $1.1B, granting worldwide rights outside Greater China to develop, manufacture, and commercialize the oral VAV1-directed molecular glue degrader. The deal is exclusive to Evommune for that region.Seeking AlphaEvommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases Prepared Remarks TranscriptEvommune announced an agreement with Hinova for global development rights to EVO570, an oral VAV1 molecular glue degrader, excluding Greater China. The company's CEO Luis Peña explained the deal's rationale and the science behind EVO570, which targets VAV1, a protein found almost exclusively in immune cells.